Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant’s<\/a> Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib drug for treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).<\/p>\n Conducted over more than 96 weeks, the first trial “significantly reduced the annualized relapse rate (ARR) compared to teriflunomide,” an RMS drug developed by Sanofi and currently available as a generic from multiple manufacturers.<\/p>\n The second trial compared fenebrutinib to ocrelizumab, an MS drug developed by Roche itself and not available as a generic, in treatment of PPMS. This trial confirmed fenebrutinib is at least “non-inferior compared to ocrelizumab,” which in turn is currently “the only approved therapy in PPMS.” This second trial lasted more than 120 weeks.<\/p>\n Overall, Roche says “fenebrutinib substantially reduced the number of relapses in RMS and slowed disability progression in PPMS” — two separate uses for one MS drug in a market that’s been estimated at $27.8 billion in annual sales last year, with likely growth to $46.4 billion by 2033.<\/p>\n Clinical trial work<\/a> on fenebrutinib is ongoing.<\/p>\n Valued in excess of $296 billion, Roche stock sells for 25.3 times trailing earnings but less than 15 times free cash flow. (At $19.9 billion generated over the past year, Roche generates nearly 70% more cash profit than it reports as net income.) The company also pays a very respectable 3.8% dividend yield.<\/p>\n Were Roche growing just a bit faster than the 6% annualized long-term growth rate that analysts project for it, the stock might already be a buy. As things stand, though, I still need to see Roche stock get cheaper before I can call it a buy.<\/p>\n Before you buy stock in Roche Holding AG, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Roche Holding AG wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $595,194!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,153,334!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 1,036% \u2014 a market-crushing outperformance compared to 191% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of November 10, 2025<\/p>\n Rich Smith<\/a> has no position in any of the stocks mentioned. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy<\/a>.<\/p>\n![\"Scientist](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/3144054e70d380d9bdd9951e342cb65e.jpeg\")
Image source: Getty Images. <\/p>\n